Report of Foreign Issuer (6-k)
August 22 2019 - 4:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2019
Commission File Number
001-37846
CELLECT BIOTECHNOLOGY
LTD.
(Translation of registrant’s name into
English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
This Form 6-K is incorporated by reference
into the registrant’s Registration Statements on Form S-8 (Registration No. 333-214817, 333-220015 and 333-225003) and on
Form F-3 (Registration No. 333-229083, 333-219614 and 333-212432).
On August 20, 2019, Ruhama Avraham resigned
as a director of Cellect Biotechnology Ltd., effective immediately, so she can focus on the demands of a newly appointed position.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Cellect Biotechnology Ltd.
|
|
|
|
|
By:
|
/s/ Eyal Leibovitz
|
|
|
Name: Eyal Leibovitz
|
Date: August 22, 2019
|
|
Title: Chief Financial Officer
|
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Aug 2023 to Aug 2024